Drug Trial Radar · NCT00542178
Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)
Last checked: Nov 20, 2026Latest source record: Jul 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,472
Actual
Start
Oct 2003
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)NIH
- Sponsor type
- NIH
- Collaborators
- National Eye Institute (NEI)
- First posted
- Oct 10, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.
Conditions
- Diabetic Retinopathy
Interventions
Hypoglycemic AgentsDrug
Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
Standard glycemia controlDrug
A strategy of glycemia drugs for HbA1c 7% - 7.9%
Intensive BP treatmentDrug
A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
Standard BP controlDrug
A strategy of BP drugs for SBP less than 140 mm Hg
FenofibrateDrug
Blinded fenofibrate
SimvastatinDrug
Simvastatin 20-40 mg/d
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of Proliferative Diabetic Retinopathy Necessitating Photocoagulation Therapy or VitrectomyTime frame: Measured at Year 4
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
The Berman Center for Clinical Research
Minneapolis, Minnesota
Columbia University
New York, New York
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Case Western Reserve University
Cleveland, Ohio
Veterans Affairs
Memphis, Tennessee
University of Washington
Seattle, Washington
McMaster University
Hamilton, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.